Combination Therapy With Oral Sildenafil and Beraprost for Pulmonary Arterial Hypertension Associated With CREST Syndrome
|
|
- Walter Logan
- 6 years ago
- Views:
Transcription
1 Combination Therapy With Oral Sildenafil and Beraprost for Pulmonary Arterial Hypertension Associated With CREST Syndrome Kenji MIWA, 1 MD, Takashi MATSUBARA, 1 MD, Yoshihide UNO, 1 MD, Toshihiko YASUDA, 1 MD, Kenji SAKATA, 1 MD, Toyonobu TSUDA, 1 MD, and Honin KANAYA, 1 MD SUMMARY Pulmonary arterial hypertension (PAH) is commonly associated with CREST (Calcinosis, Raynaud phenomenon, Esophageal motility disorders, Sclerodactyly, and Telangiectasia) syndrome. Sildenafil, an oral phosphodiesterase type-5 inhibitor, may offer benefits in the pharmacological management of PAH. However, little is known about the long-term hemodynamic effects of sildenafil, and the potential role of sildenafil in longterm combination with beraprost, an oral prostacyclin analogue, remains unclear. We therefore examined the hemodynamic effect of oral sildenafil alone and when coadministered with beraprost in a patient with PAH associated with CREST syndrome. Traces of the acute hemodynamic effects of beraprost (20 µg) disappeared after 2 hours. In contrast, the acute hemodynamic effects of sildenafil (50 mg) produced a greater reduction in PAP (31%) and PVR (40%), and these effects also disappeared after 5 hours. After 1 month of combination therapy of sildenafil (25 mg) twice daily and beraprost (20 µg) 3 times daily, the fall in pulmonary artery pressure and pulmonary vascular resistance was sustained (31% in both). Furthermore, the patient had significantly improved her 3-minute walk test and NYHA function class without significant adverse effects at the reported doses. The findings indicate that oral sildenafil is a potent pulmonary vasodilator that appears to act synergistically with oral beraprost to cause sustained pulmonary vasodilatation in a patient with PAH associated with CREST syndrome. (Int Heart J 2007; 48: ) Key words: Pulmonary artery hypertension, CREST syndrome, Sildenafil, Beraprost PULMONARY artery hypertension (PAH) is a life-threatening disease characterized by progressive pulmonary hypertension that leads to right ventricular failure and death. 1) PAH comprises idiopathic PAH and PAH in the setting of collagen disease (eg, in localized cutaneous systemic sclerosis, also known as the From the 1 Department of Cardiology, Ishikawa Prefectural Central Hospital, Ishikawa, Japan. Address for correspondence: Kenji Miwa, MD, Department of Cardiology, Ishikawa Prefectural Central Hospital, Kuratsuki-higashi 2-1, Kanazawa, Ishikawa , Japan. Received for publication November 1, Revised and accepted February 19,
2 418 MIWA, ET AL Int Heart J May 2007 CREST syndrome), congenital systemic to pulmonary shunts, portal hypertension, and HIV infection. All these conditions exhibit virtually identical obstructive pathologic changes in the pulmonary microcirculation. 2) Median survival is 2.8 years from the time of diagnosis. Therefore, a novel therapeutic strategy for PAH is desirable. A number of vasodilating agents, including adenosine, nitroprusside, calcium antagonists, and prostacyclin have been tested as the basis for long-term therapy. Unfortunately, these vasodilator therapies have limited efficacy due to lack of selectivity for pulmonary vasculature. Sildenafil 3-5) is a specific inhibitor of phosphodiesterase isoform 5 (PDE5) and induces smooth-muscle relaxation via a nitric oxide (NO) dependent increase of cyclic guanosine 5-monophosphate. Lung PDE5 inhibition by sildenafil may thus reduce pulmonary vascular pressures along this pathway. Uncontrolled clinical studies have examined the acute hemodynamic effects of sildenafil and its potential role in the long-term treatment of patients with PAH. However, little is known about the long-term hemodynamic effects of sildenafil, and its potential role in long-term combination therapy remains unclear. On the other hand, prostacyclin produces strong vasodilatation and inhibition of platelet aggregation. Beraprost is the first chemically stable and orally active prostacyclin analogue, 6) and is an approved therapy for PAH in Japan. Considering that sildenafil and beraprost dilate pulmonary vessels through different mechanisms, combination therapy with both drugs may have additive or synergistic effects on pulmonary hemodynamics. We report on a case that demonstrated an acute response to oral sildenafil alone, as well as a sustained response in combination with oral beraprost, which we believe to justify detailed long-term studies looking at symptomatic and prognostic benefit for patients with PAH. CASE A 63-year-old Japanese woman with a 30-year history of CREST syndrome was admitted to our hospital because of worsening dyspnea and palpitations upon exertion. Primary biliary cirrhosis and chronic thyroiditis had been diagnosed 13 years previously. Physical examination revealed mild facial and manual telangiectasias, prominent right ventricular impulse, increased P 2, a holosystolic murmur at the left lower sternal border, trace ankle edema, and sclerodactyly. Oxygen saturation of hemoglobin with the patient at rest without oxygen supplementation was 95%. Chest radiography revealed moderate cardiomegaly, and echocardiography showed a steady increase in pulmonary artery pressure with right ventricular enlargement. There was no evidence of pulmonary embolism according to
3 Vol 48 No 3 SILDENAFIL ACTS SYNERGISTICALLY WITH BERAPROST 419 perfusion scinti-scanning of the lung. At catheterization, the right jugular vein and radial artery were cannulated. Left-heart catheterization revealed normal coronary arteries and left ventricular function. Right-heart catheterization revealed an increased pulmonary artery pressure (PAP) of 59/24 mmhg (normal range, 15-30/4-12 mmhg), mean PAP of 35 mmhg (normal range, 9-19 mmhg), systemic arterial pressure (SAP) of 164/ 90 mmhg (normal value, < 140/ < 90 mmhg), mean SAP of 114 mmhg, cardiac index of 2.4 L/m 2 per minute (normal range, L/m 2 per minute), systemic vascular resistance (SVR) of 2683 dyne s/cm 5 (normal range, dyne s/ cm 5 ), and pulmonary vascular resistance (PVR) of 748 dyne s/cm 5 (normal range, dyne s/cm 5 ). Cardiopulmonary hemodynamics were then monitored before and every 1 hour after administration of oral beraprost 20 µg. After 1 hour, mpap and PVR were reduced by 9% and 10%, respectively. Her cardiac index improved 11%. This acute hemodynamic effect of beraprost disappeared after 2 hours. The next day after receiving written informed consent, sildenafil 50 mg was administered. After 3 hours, sildenafil reduced mpap and PVR by a maximum of 30% and 40%, respectively. The cardiac index improved 7%. The acute hemodynamic effect of sildenafil disappeared after 5 hours (Figure 1). Figure 1. Acute response of mean pulmonary artery pressure (mpap) and pulmonary vascular resistance (PVR) to beraprost (20 µg) and sildenafil (50 mg).
4 420 MIWA, ET AL Int Heart J May 2007 Figure 2. Percent change in hemodynamic parameters from baseline at 1 month after combination therapy with sildenafil (25 mg) twice daily and beraprost (20 µg) three times daily. The last oral doses of sildenafil and beraprost were given 15 hours before the procedure. mpap and PVR both showed sustained 31% drops, while mbp and SVR show sustained drops of 19% and 17%, respectively. Combination therapy clearly exhibited sustained efficacy and selectivity for pulmonary vasculature. After ingesting a 50 mg sildenafil tablet, the patient suffered a headache and refused another 50 mg dose. We therefore reduced treatment to a single dose of sildenafil. She was started on a combination therapy of sildenafil 25 mg twice daily and beraprost 20 µg three times daily. She experienced an improvement of dyspnea upon exertion 1 week after starting combination therapy, with further improvements over the following 1 month. Long-term hemodynamic effects were assessed by cardiac catheterization at 1 month (Figure 2). The last oral doses of sildenafil and beraprost were given 15 hours before the procedure. Interestingly, a sustained 31% decrease in both mpap and PVR was seen, without affecting the cardiac index. In addition, sustained falls in mbp and SVR of 19% and 17%, respectively, were noted. It is clear that a combination therapy of sildenafil and beraprost possessed sustained efficacy with selectivity for the pulmonary vasculature over 1 month. Furthermore, after 1 month of combined therapy, the patient had significantly improved her 3-minute walk distance by 15% and her New York Heart Association (NYHA) heart function class returned to class II from class III. The plasma level of brain natriuretic peptide dropped from 126 pg/ml to 62 pg/ml. No significant decrease in arterial oxygen saturation and no adverse events except for transient flushing occurred during combination therapy.
5 Vol 48 No 3 SILDENAFIL ACTS SYNERGISTICALLY WITH BERAPROST 421 DISCUSSION We first examined the acute hemodynamic effects of sildenafil and beraprost separately for a patient with PAH. The acute hemodynamic effects of beraprost 20 µg alone were quite small and disappeared after 2 hours. In fact, in 2 randomized, double-blind, placebo-controlled trials (RCTs) which studied beraprost in PAH, 7,8) no significant changes in cardiopulmonary hemodynamics and no difference in survival were observed between the 2 treatment arms. In contrast, the acute hemodynamic effects of sildenafil 50 mg alone produced a greater reduction in PAP (30%) and PVR (40%); however, these effects also disappeared after 5 hours. These results were compatible with the previously reported acute hemodynamic effects of sildenafil. 9-11) In any event, the long-term hemodynamic effects of sildenafil remain controversial, 9,11) and little is known about the potential role of sildenafil in long-term combination therapy. We next examined the chronic hemodynamic effects of a combination therapy of sildenafil and beraprost. After 1 month, it was clear that this combination manifests sustained efficacy as well as pulmonary vasculature selectivity without significant adverse effect at the reported doses. In light of the short duration of these drugs when given alone, as well as the small amounts administered (sildenafil 25 mg twice daily, beraprost 20 µg three times daily), these chronic hemodynamic results may well be due to a synergistic effect of sildenafil and beraprost together. As to a possible mechanism of synergy between these drugs, Niwano, et al 12) have demonstrated that treatment of cultured human and bovine aortic endothelial cells with beraprost increased enos expression through the camp responsive elements, which indicates a close link between the PGI2 signal and NO pathways. The mechanism underlying the augmented response with sildenafil and prostanoids is incompletely understood, but these findings suggest significant cross talk between the cyclic nucleotides. Itoh, et al 13) also demonstrated the additive effect of sildenafil and beraprost using an animal model of PAH. Stiebellehner, et al 11) treated 3 patients with PAH who were doing poorly despite long-term IV epoprostenol therapy, and reported hemodynamic and clinical improvements with the addition of sildenafil. However, continuous intravenous administration of epoprostenol is limited by serious infectious complications of the intravenous line, systemic side effects due to the nonselectivity of the vasodilator response, and extremely high costs incurred by tachyphylaxis with long-term administration. Thus, the potential utility of sildenafil and beraprost has particular appeal as a long-term treatment due to its ease of oral administration. Recently, Ikeda, et al 14) reported that the addition of oral sildenafil to bera-
6 422 MIWA, ET AL Int Heart J May 2007 prost for patients with pulmonary hypertension represents a safe and effective treatment in the acute phase. However, the effects of long-term use in chronic cases remain unclear. Our study leads us to believe that in combination with beraprost, sildenafil treatment may possess synergistic hemodynamic effects with no loss of selectivity for the pulmonary vasculature for a duration of at least 1 month. It should be noted that the severity of PAH was milder in our patient compared to other cases reporting the use of sildenafil. Combined sildenafil/beraprost therapy may thus prove more effective in patients with early stage PAH. In conclusion, appropriately designed RCTs are needed to compare the long-term efficacy of sildenafil with beraprost in patients with PAH. REFERENCES 1. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989; 80: Zhao L, Mason NA, Morrell NW, et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001; 104: Kleinsasser A, Loeckinger A, Hoermann C. Sildenafil modulates hemodynamics and pulmonary gas exchange. Am J Respir Crit Care Med 2001; 163: Ghofrani HA, Schermuly RT, Rose F, et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2003; 167: Nishio S, Kurumatani H. Pharmacological and clinical properties of beraprost sodium, orally active prostacyclin analogue. Nippon Yakurigaku Zasshi 2001; 117: (Review) (Japanese) 7. Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39: Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: Watanabe H, Ohashi K, Takeuchi K, et al. Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther 2002; 71: Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002; 105: Stiebellehner L, Petkov V, Vonbank K, et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest 2003; 123: Niwano K, Arai M, Tomaru K, Uchiyama T, Ohyama Y, Kurabayashi M. Transcriptional stimulation of the enos gene by the stable prostacyclin analogue beraprost is mediated through camp-responsive element in vascular endothelial cells: close link between PGI2 signal and NO pathways. Circ Res 2003; 93: Itoh T, Nagaya N, Fujii T, et al. A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med 2004; 169: Ikeda D, Tsujino I, Ohira H, et al. Addition of oral sildenafil to beraprost is a safe and effective therapeutic option for patients with pulmonary hypertension. J Cardiovasc Pharmacol 2005; 45:
Role of Combination PAH Therapies
Role of Combination PAH Therapies Ronald J. Oudiz, MD, FACP, FACC Associate Professor of Medicine, David Geffen School of Medicine at UCLA Director, Liu Center for Pulmonary Hypertension Los Angeles Biomedical
More informationPharmacy Management Drug Policy
SUBJECT: Pulmonary Arterial Hypertension (PAH) POLICY NUMBER: Pharmacy-42 Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed
More informationPULMONARY HYPERTENSION
PULMONARY HYPERTENSION REVIEW & UPDATE Olga M. Fortenko, M.D. Pulmonary & Critical Care Medicine Pulmonary Vascular Diseases Sequoia Hospital 650-216-9000 Olga.Fortenko@dignityhealth.org Disclosures None
More informationNational Horizon Scanning Centre. Tadalafil for pulmonary arterial hypertension. October 2007
Tadalafil for pulmonary arterial hypertension October 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationPulmonary Hypertension in 2012
Pulmonary Hypertension in 2012 Evan Brittain, MD December 7, 2012 Kingston, Jamaica VanderbiltHeart.com Disclosures None VanderbiltHeart.com Outline Definition and Classification of PH Hemodynamics of
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Drugs for the treatment of Draft remit / appraisal objective: Draft scope To appraise the clinical and cost effectiveness
More informationTherapeutic approaches in P(A)H and the new ESC Guidelines
Therapeutic approaches in P(A)H and the new ESC Guidelines Jean-Luc Vachiéry, FESC Head Pulmonary Vascular Diseases and Heart Failure Clinic Hôpital Universitaire Erasme Université Libre de Bruxelles Belgium
More informationRecent Treatment of Pulmonary Artery Hypertension. Cardiology Division Yonsei University College of Medicine
Recent Treatment of Pulmonary Artery Hypertension Cardiology Division Yonsei University College of Medicine Definition Raised Pulmonary arterial pressure (PAP) WHO criteria : spap>40 mmhg NIH Criteria
More informationPharmacy Management Drug Policy
SUBJECT: POLICY NUMBER: PHARMACY-42 EFFECTIVE DATE: 6/2005 LAST REVIEW DATE: 4/19/2018 If the member s subscriber contract excludes coverage for a specific service or prescription drug, it is not covered
More informationPulmonary Hypertension Perioperative Management
Pulmonary Hypertension Perioperative Management Bruce J Leone, MD Professor of Anesthesiology Chief, Neuroanesthesiology Vice Chair for Academic Affairs Mayo Clinic Jacksonville, Florida Introduction Definition
More information1. Phosphodiesterase Type 5 Enzyme Inhibitors: Sildenafil (Revatio), Tadalafil (Adcirca)
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutic
More informationPulmonary Hypertension. Murali Chakinala, M.D. Washington University School of Medicine
Pulmonary Hypertension Murali Chakinala, M.D. Washington University School of Medicine Pulmonary Circulation Alveolar Capillary relationship Pulmonary Circulation High flow, low resistance PVR ~1/15 of
More informationOral Therapies for Pulmonary Arterial Hypertension
Oral Therapies for Pulmonary Arterial Hypertension Leslie Wooten, PharmD PGY2 Internal Medicine Pharmacy Resident University of Cincinnati Medical Center April 30 th, 2018 Objectives Pharmacist Objectives
More informationAdvances in Pharmacotherapy of PAH
24 th Annual Advances in Heart Disease Advances in Pharmacotherapy of PAH Gabriel Gregoratos, MD 12/14/2007 UCSF Cardiology 1 Faculty Disclosure Statement for Gabriel Gregoratos, MD Nothing to disclose
More informationChronic Thromboembolic Pulmonary Hypertention CTEPH
Chronic Thromboembolic Pulmonary Hypertention CTEPH Medical Management Otto Schoch, Prof. Dr. Klinik für Pneumologie und Schlafmedizin Kantonsspital St.Gallen CTEPH: Medical Management Diagnostic aspects
More informationNational Horizon Scanning Centre. Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class III. April 2008
Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class April 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationAnjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced
Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced Heart Failure & Cardiac Transplant Temple University
More informationPulmonary Hypertension. Pulmonary Arterial Hypertension Diagnosis, Impact and Outcomes
Pulmonary Hypertension Pulmonary Arterial Hypertension Diagnosis, Impact and Outcomes Pulmonary Arterial Hypertension Disease of small pulmonary arteries Characteristic changes Medial hypertrophy Intimal
More informationMACITENTAN DEVELOPMENT IN CHILDREN WITH PULMONARY HYPERTENSION (PAH)
MACITENTAN DEVELOPMENT IN CHILDREN WITH PULMONARY HYPERTENSION (PAH) ORPHAN DRUG AND RARE DISEASE 11 MAY 2017 Catherine Lesage, MD, Pediatrics Program Head, Actelion Copyright AGENDA Pulmonary Arterial
More informationBosentan for treatment of pulmonary arterial hypertension (I)
KEY PAPER EVALUATION Bosentan for treatment of pulmonary arterial hypertension (I) Sabina A Antoniu University of Medicine and Pharmacy, Clinic of Pulmonary Disease, 62 Costache Negri St, Bl.C2, Sc.A,
More informationACCP PAH Medical Therapy Guidelines: 2007 Update. David Badesch, MD University of Colorado School of Medicine Denver, CO
ACCP PAH Medical Therapy Guidelines: 2007 Update David Badesch, MD University of Colorado School of Medicine Denver, CO Disclosure of Commercial Interest Dr. Badesch has received grant/research support
More informationPulmonary Hypertension: Another Use for Viagra
Pulmonary Hypertension: Another Use for Viagra Kathleen Tong, MD Director, Heart Failure Program Assistant Clinical Professor University of California, Davis Disclosures I have no financial conflicts A
More informationThe Case of Marco Nazzareno Galiè, M.D.
The Case of Marco Nazzareno Galiè, M.D. DIMES Disclosures Consulting fees and research support from Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly and Co, GlaxoSmithKline and Pfizer Ltd Clinical
More informationDoes Tadalafil Improve Exercise Capacitance in Patients over 12 Years Old with Pulmonary Hypertension?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2012 Does Tadalafil Improve Exercise Capacitance
More informationDr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college
Dr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college PULMONARY HYPERTENSION Difficult to diagnose early Because Not detected during routine physical examination and Even in advanced cases symptoms
More informationPatient Case. Patient Case 6/1/2013. Treatment of Pulmonary Hypertension in a Community
Treatment of Pulmonary Hypertension in a Community Hospital Serena Von Ruden, PharmD, RN, BSN St. Francis Hospital Federal Way, WA Franciscan Health System HPI: 66 year old male with advanced oxygendependent
More informationScottish Medicines Consortium
Scottish Medicines Consortium sildenafil, 20mg (as citrate) tablets (Revatio ) No. (596/10) Pfizer Ltd 15 January 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationPULMONARY ARTERIAL HYPERTENSION AGENTS
Approvable Criteria: PULMONARY ARTERIAL HYPERTENSION AGENTS Brand Name Generic Name Length of Authorization Adcirca tadalafil Calendar Year Adempas riociguat Calendar Year Flolan epoprostenol sodium Calendar
More informationDr. J. R. Rawal 1 ; Dr. H. S. Joshi 2 ; Dr. B. H. Roy 3 ; Dr. R. V. Ainchwar 3 ; Dr. S. S. Sahoo 3 ; Dr. A. P. Rawal 4 ; Dr. R. A.
(6) EFFECT OF ORAL SILDENAFIL ON RESIDUAL PULMONARY ARTERIAL HYPERTENSION IN PATIENTS FOLLOWING SUCCESSFUL PERCUTANEOUS BALLOON MITRAL VALVULOPLASTY (PBMV): SHORT TERM RESULTS IN 12 PATIENTS. Dr. J. R.
More informationClinical Efficacy of Sildenafil in Primary Pulmonary Hypertension A Randomized, Placebo-Controlled, Double-Blind, Crossover Study
Journal of the American College of Cardiology Vol. 43, No. 7, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2003.10.056
More informationLong-Term Vardenafil Therapy Improves Hemodynamics in Patients with Pulmonary Hypertension
123 Case Report Hypertens Res Vol.29 (26) No.2 p.123-128 Long-Term Vardenafil Therapy Improves Hemodynamics in Patients with Pulmonary Hypertension Kazunori AIZAWA 1), Takeshi HANAOKA 1), Hiroki KASAI
More informationEfficacy and Limitations of Continuous Intravenous Epoprostenol Therapy for Idiopathic Pulmonary Arterial Hypertension in Japanese Children
Circ J 2007; 71: 1785 1790 Efficacy and Limitations of Continuous Intravenous Epoprostenol Therapy for Idiopathic Pulmonary Arterial Hypertension in Japanese Children Tomotaka Nakayama, MD; Hiromitsu Shimada,
More informationProstacyclin has potent vasodilatory,
Eur Respir Rev 29; 18: 111, 29 34 DOI: 1.1183/95918.11111 CopyrightßERSJ Ltd 29 Inhaled iloprost for the treatment of pulmonary hypertension H. Olschewski ABSTRACT: Prostacyclin and its analogues (prostanoids)
More informationDisclosures. Inhaled Therapy in Pediatric Pulmonary Hypertension. Inhaled Prostacyclin: Rationale. Outline
Disclosures Inhaled Therapy in Pediatric Pulmonary Hypertension The University of Colorado receives fees for Dr Ivy to be a consultant for Actelion, Gilead, Lilly, Pfizer, and United Therapeutics Dunbar
More informationEffectively treating patients with pulmonary hypertension: The next chapter. Lowering PAP will improve RV function in PH
Effectively treating patients with pulmonary hypertension: The next chapter Stuart Rich, M.D. Hemodynamic Progression of PAH Preclinical Symptomatic/ Stable Pulmonary Pressure Progressive/ Declining Level
More informationIntravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension
Eur Respir J 2002; 20: 339 343 DOI: 10.1183/09031936.02.02462001 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Intravenous iloprost for
More informationSevere pulmonary hypertension is a debilitating disease. Article
Article Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension Hossein Ardeschir Ghofrani, MD; Ralph Wiedemann, MD; Frank Rose, MD; Horst Olschewski, MD; Ralph
More informationNavigating the identification, diagnosis and management of pulmonary hypertension using the updated ESC/ERS guidelines
Navigating the identification, diagnosis and management of pulmonary hypertension using the updated ESC/ERS guidelines Host: Marc Humbert Speaker: Simon Gibbs Marc HUMBERT, MD, PhD Professor of Respiratory
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 1998, by the Massachusetts Medical Society VOLUME 338 J ANUARY 29, 1998 NUMBER 5 REDUCTION IN PULMONARY VASCULAR RESISTANCE WITH LONG-TERM EPOPROSTENOL (PROSTACYCLIN)
More informationTreprostinil-Based Therapy in the Treatment of Moderate-to-Severe Pulmonary Arterial Hypertension* Long-term Efficacy and Combination With Bosentan
CHEST Treprostinil-Based Therapy in the Treatment of Moderate-to-Severe Pulmonary Arterial Hypertension* Long-term Efficacy and Combination With Bosentan Raymond L. Benza, MD; Barry K. Rayburn, MD; Jose
More informationEffective Strategies and Clinical Updates in Pulmonary Arterial Hypertension
Effective Strategies and Clinical Updates in Pulmonary Arterial Hypertension Hap Farber Director, Pulmonary Hypertension Center Boston University School of Medicine Disclosures 1) Honoria: Actelion, Gilead,
More informationCardiac Catheterization is Unnecessary in the Evaluation of Patients with Pulmonary Hypertension: CON
Cardiac Catheterization is Unnecessary in the Evaluation of Patients with Pulmonary Hypertension: CON Dunbar Ivy, MD The Children s s Hospital Heart Institute 1 Diagnostic Evaluation: Right Heart Cardiac
More informationThe Case of Lucia Nazzareno Galiè, M.D.
The Case of Lucia Nazzareno Galiè, M.D. DIMES Disclosures Consulting fees and research support from Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly and Co, GlaxoSmithKline and Pfizer Ltd Clinical
More informationReview Article Diagnosis and Management of Pulmonary Arterial Hypertension
Pulmonary Medicine Volume 2011, Article ID 845864, 13 pages doi:10.1155/2011/845864 Review Article Diagnosis and Management of Pulmonary Arterial Hypertension Jeanne Houtchens, Douglas Martin, and James
More informationΠνευμονική Υπέρταση Ι.Ε. ΚΑΝΟΝΙΔΗΣ
Πνευμονική Υπέρταση Ι.Ε. ΚΑΝΟΝΙΔΗΣ PH is defined as PAPm 25 mm Hg at rest The general definition of PH remains unchanged Most of the relevant epidemiological and therapeutic studies have used the 25 mm
More informationPulmonary Hypertension: Evolution and
Management of Pulmonary Hypertension: Evolution and Controversies VERMONT CARDIAC NETWORK SPRING CONFERENCE MAY 10, 2018 MARYELLEN ANTKOWIAK, MD, PULMONARY & CRITICAL CARE MEDICINE, UVMMC WHO classification
More informationPulmonary Vasodilator Treatments in the ICU Setting
Pulmonary Vasodilator Treatments in the ICU Setting Lara Shekerdemian Circulation 1979 Ann Thorac Surg 27 Anesth Analg 211 1 Factors in the ICU Management of Pulmonary Hypertension After Cardiopulmonary
More informationPharmacy Management Drug Policy
SUBJECT: POLICY NUMBER: PHARMACY-42 EFFECTIVE DATE: 6/2005 LAST REVIEW DATE: 10/1/2018 If the member s subscriber contract excludes coverage for a specific service or prescription drug, it is not covered
More informationPulmonary arterial hypertension. Pulmonary arterial hypertension: newer therapies. Definition of PH 12/18/16. WHO Group classification of PH
Pulmonary arterial hypertension Pulmonary arterial hypertension: newer therapies Ramona L. Doyle, MD Clinical Professor of Medicine, UCSF Attending Physician UCSF PH Clinic Definition and classification
More informationPulmonary Hypertension: Clinical Features & Recent Advances
Pulmonary Hypertension: Clinical Features & Recent Advances Lisa J. Rose-Jones, MD Assistant Professor of Medicine, Division of Cardiology Advanced Heart Failure/Cardiac Transplantation & Pulmonary Hypertension
More informationAbstract Book. Inspiring Approaches to Clinical Challenges in Pulmonary Hypertension
Inspiring Approaches to Clinical Challenges in Pulmonary Hypertension Abstract Book A symposium sponsored by Bayer Schering Pharma at ERS 2008 Annual Congress www.ventavis.com Welcome Dear Colleague, It
More informationADVANCED THERAPIES FOR PHARMACOLOGICAL TREATMENT OF PULMONARY HYPERTENSION
Status Active Medical and Behavioral Health Policy Section: Medicine Policy Number: II-107 Effective Date: 04/21/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members
More informationMedical Therapy for Chronic Thromboembolic Pulmonary Hypertension
Medical Therapy for Chronic Thromboembolic Pulmonary Hypertension Josanna Rodriguez-Lopez, MD Pulmonary Hypertension and Thromboendarterectomy Program Massachusetts General Hospital Harvard Medical School
More informationDefinition: HPS is a disease process with a triad of: 1- Liver disease. 2- Widespread intrapulmonary vasodilatation. 3- Gas exchange abnormality prese
Hepatopulmonary syndrome (HPS) By Alaa Haseeb, MS.c Definition: HPS is a disease process with a triad of: 1- Liver disease. 2- Widespread intrapulmonary vasodilatation. 3- Gas exchange abnormality presenting
More information5/30/2014. Pulmonary Hypertension PULMONARY HYPERTENSION. mean PAP > 25 mmhg at rest. Disclosure: none
Disclosure: Pulmonary Hypertension none James Ramsay MD Medical Director, CV ICU, Moffitt Hospital, UCSF PULMONARY HYPERTENSION mean PAP > 25 mmhg at rest Pulmonary Hypertension and Right Ventricular Dysfunction:
More informationPULMONARY HYPERTENSION & THALASSAEMIA
3rd Pan-American Thalassaemia Conference Buenos Aires 2010 Dr Malcolm Walker Cardiologist University College & the Heart Hospital LONDON Clinical Director Hatter Cardiovascular Institute - UCLH PULMONARY
More informationTeaching Round Claudio Sartori
Teaching Round 14.03.2017 Claudio Sartori Cas clinique Femme 47 ans, connue pour un BPCO, asthénie, douleurs thoraciques, dyspnée à l effort, œdèmes membres inférieurs, deux syncopes. Tabac, BMI 31 kg/m2
More informationSotatercept PULSAR Phase 2 PAH Webinar. March 28, 2018
Sotatercept PULSAR Phase 2 PAH Webinar March 28, 2018 Acceleron Forward-Looking Statements THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS ABOUT THE COMPANY S STRATEGY, FUTURE PLANS and prospects,
More informationPulmonary Hypertension: When to Initiate Advanced Therapy. Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University
Pulmonary Hypertension: When to Initiate Advanced Therapy Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University Disclosures Medtronic, Abbott: Consultant Hemodynamic Definition of
More informationRiociguat for chronic thromboembolic pulmonary hypertension
Riociguat for chronic thromboembolic pulmonary hypertension This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT
European Medicines Agency London, 18 December 2008 Doc. Ref. EMEA/CHMP/EWP/356954/2008 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT CHMP GUIDELINE ON THE CLINICAL INVESTIGATIONS OF MEDICINAL
More informationPrimary Pulmonary Hypertension
PULMONARY DISEASE BOARD REVIEW MANUAL PUBLISHING STAFF PRESIDENT, GROUP PUBLISHER Bruce M. White EDITORIAL DIRECTOR Debra Dreger SENIOR EDITOR Becky Krumm, ELS ASSOCIATE EDITOR Lamont Williams ASSISTANT
More informationClinical Policy: Macitentan (Opsumit) Reference Number: ERX.SPMN.88
Clinical Policy: (Opsumit) Reference Number: ERX.SPMN.88 Effective Date: 07/16 Last Review Date: 06/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationSildenafil Citrate Therapy for Pulmonary Arterial Hypertension
The new england journal of medicine original article Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension Nazzareno Galiè, M.D., Hossein A. Ghofrani, M.D., Adam Torbicki, M.D., Robyn J. Barst,
More informationPulmonary Arterial Hypertension (PAH) Treatments
Care1st Health Plan Arizona, Inc. Easy Choice Health Plan Harmony Health Plan of Illinois Missouri Care Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona OneCare (Care1st Health
More informationRaymond L. Benza, MD, a Mardi Gomberg-Maitland, MD, MSc, b Robert Naeije, MD, PhD, c Carl P. Arneson, MStat, d and Irene M.
http://www.jhltonline.org Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled
More informationUpdate in Pulmonary Arterial Hypertension
Update in Pulmonary Arterial Hypertension Michael J Sanley, MD April 12, 2018 Disclosures I have nothing to disclose 2 1 Case Presentation 67 yo male with atrial fibrillation, CLL on IVIG, presents with
More informationPulmonary Hypertension Drugs
Pulmonary Hypertension Drugs Policy Number: Original Effective Date: MM.04.028 10/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO 05/25/2012 Section: Prescription Drugs Place(s) of Service:
More informationPulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension
Respiratory Medicine (2010) 104, 481e496 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed REVIEW Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary
More informationTHERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines
THERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines Vu Nang Phuc, MD Dinh Duc Huy, MD Pham Nguyen Vinh, MD, PhD, FACC Tam Duc Cardiology Hospital Faculty Disclosure No conflict of interest
More informationWHY ADMINISTER CARDIOTONIC AGENTS?
Cardiac Pharmacology: Ideas For Advancing Your Clinical Practice The image cannot be displayed. Your computer may not have enough memory to open the image, or Roberta L. Hines, M.D. Nicholas M. Greene
More informationManaging Multiple Oral Medications
Managing Multiple Oral Medications Chris Archer-Chicko, MSN, CRNP PENN Presbyterian Medical Center Arlene Schiro,, CRNP Massachusetts General Hospital Mary Bartlett, CRNP Winthrop University Hospital PH
More informationSildenafil Citrate Powder. Sildenafil citrate powder. Description. Section: Prescription Drugs Effective Date: January 1, 2016
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.06.15 Subject: Sildenafil Citrate Powder Page: 1 of 6 Last Review Date: December 3, 2015 Sildenafil Citrate
More informationIn focus The paediatric PAH population Clinicians Perspectives
In focus The paediatric PAH population Clinicians Perspectives Maurice Beghetti Pediatric Cardiology University Children s Hospital HUG and CHUV Pulmonary Hypertension Program HUG Centre Universitaire
More informationΕπεμβατικές στρατηγικές στην πνευμονική υπέρταση
Επεμβατικές στρατηγικές στην πνευμονική υπέρταση Παναγιώτης Καρυοφύλλης Καρδιολόγος Ωνάσειο Καρδιοχειρουργικό Κέντρο Mortality in PAH 2015 ESC/ERS Guidelines. Treatment algorithm Since BAS is performed
More informationTherapy Update: ERAs. Review of Mechanism. Disclosure Statements. Outline. Disclosure: Research support from United Therapeutics
1 Therapy Update: ERAs Disclosure Statements Disclosure: Research support from United Therapeutics Most of the medications discussed in this presentation are off-label usage Nidhy Varghese, MD Pulmonary
More informationReal-world experience with riociguat in CTEPH
Real-world experience with riociguat in CTEPH Matthias Held Center of Pulmonary Hypertension and Pulmonary Vascular Disease, Medical Mission Hospital, Würzburg, Germany Tuesday, 29 September ERS International
More informationAnn Vasc Dis Vol. 6, No. 3; 2013; pp Online August 12, Annals of Vascular Diseases doi: /avd.oa Original Article
Ann Vasc Dis Vol. 6, No. 3; 2013; pp 578 582 Online August 12, 2013 2013 Annals of Vascular Diseases doi:10.3400/avd.oa.13-00056 Original Article Respiratory and Hemodynamic Changes in Patients with Chronic
More informationProstanoid Therapy for Pulmonary Arterial Hypertension
Journal of the American College of Cardiology Vol. 43, No. 12 Suppl S 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.02.036
More informationPulmonary Arterial Hypertension - Overview
Pulmonary Arterial Hypertension - Overview J. Shaun Smith, MD Co-Director, Pulmonary Vascular Disease Program Assistant Professor of Medicine Division of Pulmonary, Critical Care and Sleep Medicine The
More informationPulmonary Arterial Hypertension - Overview
Pulmonary Arterial Hypertension - Overview J. Shaun Smith, MD Co-Director, Pulmonary Vascular Disease Program Assistant Professor of Medicine Division of Pulmonary, Critical Care and Sleep Medicine The
More informationHepatopulmonary Syndrome Portopulmonary Hypertension. M. Verhaegen Ochtendkrans
Hepatopulmonary Syndrome Portopulmonary Hypertension M. Verhaegen Ochtendkrans 17-8-2012 End Stage Liver Disease (ESLD) and Arterial Hypoxemia Cardiopulmonary causes irrespective of ESLD E.g. heart failure,
More informationCor pulmonale. Dr hamid reza javadi
1 Cor pulmonale Dr hamid reza javadi 2 Definition Cor pulmonale ;pulmonary heart disease; is defined as dilation and hypertrophy of the right ventricle (RV) in response to diseases of the pulmonary vasculature
More informationSumiaki Tanaka, Yu Matsueda, Tatsuhiko Wada, Junichi Tanaka, Tatsuo Nagai, Shunsei Hirohata
Original Contribution Kitasato Med J 2017; 47: 52-61 Long-term survival of patients with pulmonary arterial hypertension associated with connective tissue disease: beneficial effects of beraprost sodium,
More informationPulmonary Hypertension Drugs
Pulmonary Hypertension Drugs Policy Number: Original Effective Date: MM.04.028 10/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/22/2015 Section: Prescription Drugs
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST ESC Congress 2011 Pathophysiology of HFPEF Vascular Remodeling & Pulmonary Hypertension Carolyn S.P. Lam MBBS, MRCP, MS Case Presentation 81 yo woman with dyspnoea &
More informationProgress in PAH. Gerald Simonneau
Progress in PAH Gerald Simonneau National Reference center for Pulmonary Hypertension Bicetre University Hospital, INSERM U 999 Paris-Sud University Le Kremlin Bicêtre France Clinical Classification of
More informationThe New England Journal of Medicine LONG-TERM TREATMENT OF PRIMARY PULMONARY HYPERTENSION WITH AEROSOLIZED ILOPROST, A PROSTACYCLIN ANALOGUE.
LONG-TERM TREATMENT OF PRIMARY PULMONARY HYPERTENSION WITH AEROSOLIZED ILOPROST, A PROSTACYCLIN ANALOGUE MARIUS M. HOEPER, M.D., MICHAEL SCHWARZE, STEFAN EHLERDING, ANGELIKA ADLER-SCHUERMEYER, R.N., EDDA
More informationApproach to Pulmonary Hypertension in the Hospital
Approach to Pulmonary Hypertension in the Hospital Todd M Bull MD Professor of Medicine Director Pulmonary Vascular Disease Center Director Center for Lungs and Breathing Division of Pulmonary Sciences
More informationCurrent and Emerging Drugs in Pulmonary Vascular Pharmacology Dr AS Paul DM Seminar 08 September 06
Current and Emerging Drugs in Pulmonary Vascular Pharmacology Dr AS Paul DM Seminar 08 September 06 Pulmonary Hypertension A mean pressure of greater than 25 mm Hg at rest (normal ~14 mm Hg) or greater
More informationPulmonary arterial hypertension (PAH) is a. The use of combination therapy in pulmonary arterial hypertension: new developments REVIEW
Eur Respir Rev 2009; 18: 113, 148 153 DOI: 10.1183/09059180.00003809 CopyrightßERSJ Ltd 2009 REVIEW The use of combination therapy in pulmonary arterial hypertension: new developments N. Galiè*, L. Negro*
More informationA Patient s Guide to Understanding Pulmonary Arterial Hypertension in Systemic Sclerosis
A Patient s Guide to Understanding Pulmonary Arterial Hypertension in Systemic Sclerosis Compared with the general population, patients with systemic sclerosis (also known as scleroderma) have a higher
More informationSildenafil And Atorvastatin Added To Bosentan As Therapy For Pulmonary Hypertension
ISPUB.COM The Internet Journal of Pulmonary Medicine Volume 6 Number 1 Sildenafil And Atorvastatin Added To Bosentan As Therapy For Pulmonary Hypertension M Gomberg-Maitland, M Gulati, V McLaughlin, S
More informationTREPROSTINIL Generic Brand HICL GCN Exception/Other TREPROSTINIL REMODULIN 23650
Generic Brand HICL GCN Exception/Other TREPROSTINIL REMODULIN 23650 SODIUM TREPROSTINIL TYVASO 36537 36539 36541 TREPROSTINIL ORENITRAM 40827 **Please use the criteria for the specific drug requested**
More informationReview of bosentan in the management of pulmonary arterial hypertension
REVIEW Review of bosentan in the management of pulmonary arterial hypertension Eli Gabbay 1 John Fraser 2 Keith McNeil 3 1 Western Australian Lung Transplant Unit and Pulmonary Hypertension Service, Royal
More information2012 CADTH Symposium. April 2012
2012 CADTH Symposium Using Mixed Treatment Comparisons to compare Oral Treatments for Pulmonary Arterial Hypertension and Inform Policy Decisions by a Public Drug Plan April 2012 Objective of this Presentation
More informationAcute Vasodilator Testing in Pulmonary Hypertension: What, When, and How?
Acute Vasodilator Testing in Pulmonary Hypertension: What, When, and How? Teresa De Marco, MD University of California, San Francisco Disclosures: Grants/Research: United Therapeutics, Lung Biotechnology,
More information4/14/2010. Pulmonary Hypertension: An Update. Tim Williamson, MD, FCCP. University of Kansas Hospital. Normal Physiology
Pulmonary Hypertension: An Update Tim Williamson, MD, FCCP Director, Pulmonary Vascular Program University of Kansas Hospital Normal Physiology 1 Pulmonary Perfusion 101 High Pressure Low Pressure Pulmonary
More informationThe Hemodynamics of PH Interpreting the numbers
The Hemodynamics of PH Interpreting the numbers Todd M Bull MD Associate Professor of Medicine Division of Pulmonary Sciences and Critical Care Medicine Pulmonary Hypertension Center University of Colorado
More informationNothing to Disclose. Severe Pulmonary Hypertension
Severe Ronald Pearl, MD, PhD Professor and Chair Department of Anesthesiology Stanford University Rpearl@stanford.edu Nothing to Disclose 65 year old female Elective knee surgery NYHA Class 3 Aortic stenosis
More information